N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=78 Nitric Oxide to Treat Pulmonary Embolism
Pulmonary Embolism
Primary: Number of Participants With Normal Right Ventricular (RV) Function and Viability — 9; 5 Participants
N/A N=25 Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Phase 2 N=60 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
Multicentric Castleman's Disease
Primary: Number of Participants With Adverse Events (AEs) — 60 Participants
N/A N=1,905 EXCEL Clinical Trial
Chronic Coronary Occlusion · Unprotected Left Main Coronary Artery Disease · Stent Thrombosis
Primary: Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke — 203; 176 Participants
N/A N=122 Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke
Stroke, Acute · Stroke · Hemiparesis
Primary: Fugl-Meyer Motor Assessment (FMA) - Motor Impairment Measure — 27.5; 29.8; 26.8; 31.8 units on a scale — p=0.18
N/A N=310 Evaluation of Trima Version 7.0 Platelets in 100% Plasma
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 92; 93; 93; 1 Participants
N/A N=168 A Clinical Trial to Evaluate Investigational Silicone Hydrogel Contact Lenses Worn Continuously for One Week
Visual Disorder
Primary: Number of First Occurred Serious and Significant Lens-related Corneal Infiltrative Event (CIE) — 14; 13; 12; 1 Number of Events
N/A N=446 REVEAL AF: Incidence of AF in High Risk Patients
Atrial Fibrillation
Primary: 18 Month Incidence Rate of Atrial Fibrillation (AF) Lasting Six or More Minutes — 29.3 percent of participants
Phase 3 N=304 Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery
Atrial Fibrillation · Atrial Flutter
Primary: Occurrence of Post-operative Atrial Fibrillation Requiring Treatment After Open Heart Surgery — 50; 56; 58; 48 Participants
Phase 2 N=90 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
Colorectal Cancer
Primary: 3-Year Disease-free Survival — 88.2 percentage of patients
Phase 4 N=62 Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty
Pain, Postoperative · Total Knee Arthroplasty (TKA)
Primary: Time to Achieve Physical Therapy Discharge Criteria as Measured by 75-feet Walk Test. {Number of Hours After Conclusion of Surgery} — 67.3; 66; 46.5 Hours — p=0.355
Phase 2 N=108 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Breast Cancer
Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001
Phase 2 N=48 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma · Mantle Cell Lymphoma · Burkitt's Lymphoma
Primary: Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria) — 25; 23; 40; 100 percentage of participants